These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 23323878)

  • 21. Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy.
    Ouwens MJ; Nauta J; Ansquer JC; Driessen S
    Curr Med Res Opin; 2015 Dec; 31(12):2273-85. PubMed ID: 26397380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
    Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
    Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
    Campbell J; Mohiuddin SM
    Drugs Today (Barc); 2010 Oct; 46(10):757-64. PubMed ID: 21076712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
    Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.
    Mohiuddin SM; Thakker KM; Setze CM; Kelly MT
    Curr Med Res Opin; 2011 May; 27(5):1067-78. PubMed ID: 21438793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
    Kipnes MS; Roth EM; Rhyne JM; Setze CM; Lele A; Kelly MT; Sleep DJ; Stolzenbach JC
    Clin Drug Investig; 2010; 30(1):51-61. PubMed ID: 19995098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
    Brautbar A; Covarrubias D; Belmont J; Lara-Garduno F; Virani SS; Jones PH; Leal SM; Ballantyne CM
    Atherosclerosis; 2011 Dec; 219(2):737-42. PubMed ID: 21889769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
    Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
    Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia.
    Guo J; Meng F; Ma N; Li C; Ding Z; Wang H; Hou R; Qin Y
    Am J Cardiol; 2012 Nov; 110(9):1296-301. PubMed ID: 22840347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
    Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
    Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statin-related adverse events: a meta-analysis.
    Silva MA; Swanson AC; Gandhi PJ; Tataronis GR
    Clin Ther; 2006 Jan; 28(1):26-35. PubMed ID: 16490577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.
    Farnier M; Marcereuil D; De Niet S; Ducobu J; Steinmetz A; Retterstøl K; Bryniarski L; Császár A; Vanderbist F
    Clin Drug Investig; 2012 Apr; 32(4):281-91. PubMed ID: 22350498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
    Díaz Rodríguez Á
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety considerations with fenofibrate/simvastatin combination.
    Filippatos TD; Elisaf MS
    Expert Opin Drug Saf; 2015; 14(9):1481-93. PubMed ID: 26134595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
    Bays HE; Roth EM; McKenney JM; Kelly MT; Thakker KM; Setze CM; Obermeyer K; Sleep DJ
    Diabetes Care; 2010 Sep; 33(9):2113-6. PubMed ID: 20573750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG; Lee JY; Kang BC
    Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
    Núñez-Cortés JM
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
    Jones PH; Goldberg AC; Knapp HR; Kelly MT; Setze CM; Stolzenbach JC; Sleep DJ
    Am Heart J; 2010 Oct; 160(4):759-66. PubMed ID: 20934572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.